Trial
NCT03422094
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Washington University School of Medicine
Collaborators
Bristol-Myers Squibb
Condition
Glioblastoma
Intervention
NeoVax
Why stopped
Manufacturer changed focus to cell therapy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-27